HEALTHCARE

DOJ and HHS’s New FCA Pilot Program

4 min. read

On October 22, 2026, the Department of Justice’s Civil Division and the Department of Health and Human Services announced a Healthcare False Claims Act Self-Disclosure Pilot Program (SDPP). Under this initiative, any healthcare provider, supplier, manufacturer, or payor that uncovers a billing or referral irregularity can resolve False Claims Act (FCA) liability and associated HHS administrative remedies through a single, coordinated settlement based on publicly disclosed financial terms. The application window is brief: complete submissions must reach the DOJ by 11:59 p.m. ET on April 22, 2027.

Qualifying Organizations

This pilot program is open to organizations that receive direct or indirect payments from federal healthcare programs like Medicare and Medicaid. To qualify, the conduct must represent a potential civil violation of the False Claims Act that is not already known to the government, itself a high hurdle to satisfy.

Government knowledge may stem from a sealed qui tam complaint, subpoena, civil investigative demand (CID), audit, or government data analytics, any of which can disqualify the conduct from the program. Furthermore, companies cannot independently confirm if a whistleblower filing remains under seal. Organizations with conduct already known to the government may still seek cooperation credit under Justice Manual § 4-4.112, but they will not receive the pilot program’s defined terms.

Submission Requirements

The protocol requires applicants to submit:

  • A comprehensive description of the conduct, the underlying legal requirements, and the relevant timeframe;
  • Supporting evidentiary exhibits;
  • A record of the remedial actions taken to stop the conduct and prevent future incidents;
  • Financial data allowing the DOJ to calculate a “Base Self-Disclosure Repayment”;
  • A designated organizational point of contact;
  • A formal certification by an authorized corporate representative confirming that the submission is both complete and truthful.

The DOJ will reject late or partial submissions, and a submitted disclosure cannot be withdrawn.

The Value of Disclosure

The most significant immediate benefit for organizations is a favorable damages multiplier. Repayment obligations range between 1.25 and 1.6 times the base repayment amount. This is substantially lower than standard treble damages (3x) under the FCA and its low end sits below the 1.5 multiplier typically applied under the HHS-OIG Health Care Fraud Self-Disclosure Protocol.

Whether a company falls within this multiplier range or not depends on multiple factors:

  • Promptness of the disclosure;
  • Duration/scope of the problematic conduct;
  • Any involvement by senior leadership;
  • Financial benefit derived by the organization;
  • For issues due to a transaction, the speed with which a buyer remediated the inherited conduct.

For Anti-Kickback Statute matters, the government determines the base amount using the remuneration and associated revenue tied to the conduct, excluding claims-paid damages, assuming there are no aggravating factors like patient harm. Claims-based errors may be quantified using accepted statistical sampling methods.

Beyond financial relief, the administrative protections can be equally valuable. The settlement release covers civil FCA liability without requiring any factual admissions. Furthermore, the HHS-OIG will not mandate a Corporate Integrity Agreement, and the Centers for Medicare & Medicaid Services (CMS) will not impose civil monetary penalties or seek revocation of Medicare enrollment. Participants also avoid the burden of duplicate filings under the OIG protocol or the CMS Self-Referral Disclosure Protocol.

Important Limits

The pilot program is strictly limited to civil matters. Conduct carrying potential criminal exposure, including certain kickback arrangements, must be routed to the DOJ’s National Fraud Enforcement Division under a separate coordination policy announced on October 15, 2026. A company that makes a criminal self-disclosure under that separate policy need not file a duplicative civil submission, though the DOJ may request supplemental information to support a civil release.

Additionally, the release is strictly confined to federal FCA liability and specified HHS authorities. In other words, it does not resolve state false claims acts or state Medicaid exposure. The protocol also provides no guidance on how the DOJ and an organization will resolve disputes regarding the scope of conduct or repayment calculations. Finally, Stark Law violations are only eligible if they simultaneously trigger FCA exposure, as the Stark Law is a strict liability statute whereas the FCA requires a knowing violation.

Practical Steps

  • Treat any internal hotline reports or audit findings pertaining to billing irregularities or referral payments as possible triggers for a privileged internal investigation.
  • Evaluate potential criminal exposure early, as this dictates which division receives the disclosure.
  • Engage financial and statistical experts immediately to model the base repayment figure and establish protocols for who will sign the certification and conduct underlying due diligence.
  • M&A buyers should audit recent healthcare acquisitions for legacy billing practices immediately. Quick remediation of inherited issues helps mitigate the final damages multiplier.
  • Act without delay: conducting a thorough internal review and producing a defensible repayment calculation requires months of preparation, and the protocol provides no extension for incomplete files.

Disclaimer: This industry insight is for general information only, is not legal advice, and does not create an attorney-client relationship.

SHARE THIS INSIGHT
Weighing a self-disclosure?Talk with an attorney well before the April 22, 2027 deadline. Early is never too early.
Schedule a consultation
KEEP READING

More insights

All insights →
HEALTHCARE

Telehealth: Cybersecurity Certifications and Frameworks

Read more
HEALTHCARE

Direct-to-Consumer (DTC) Telehealth Overview

Read more
HEALTHCARE

DOJ's New False Claims Act Policies

Read more
GET IN TOUCH
2875 NE 191st Street, Suite 500
Aventura, FL 33180
42 Broadway, 12th Floor
New York, NY 10004
835 Wilshire Boulevard, Suite 500
Los Angeles, CA 90017
© 2024-2026 Praetorian Legal ServicesAll rights reserved. Attorney advertising.Prior results do not guarantee a similar outcome.